Estrella Immunopharma, Inc. (ESLA)
Develops T-cell therapies to fight blood cancers and solid tumors.
$0.75-0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-12.5%
The outlook
ESLA is trading near its 52-week lows, well below both its 50- and 200-day averages. Analyst sentiment leans bearish overall, though the average price target sits significantly above the current price. The stock remains thinly positioned in its recent range and shows limited near-term momentum.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +1503% vs current price
Market cap
$32.2M
52-wk high
$3.15
52-wk low
$0.69
50-day avg
$1.00
200-day avg
$1.41
Trailing P/E
—